University of Nottingham

Drug manufacture

Drug manufacture - a T-junction chip for microfluidics

Our multi-disciplinary teams are developing technologies for the identification and manufacture of medicines, from precision medicines, to scale up of reactors. Our technologies aim to reduce costs, improve speed of manufacture, improve patient benefit and increase sustainability of manufacture.

3D printed drugs

Personalised medicine

We are investigating a range of new technologies that enable increased flexibility in medicine manufacture that can deliver stratified or so called precision medicines for small groups of patients.

3D printed medicines

Working with Astra Zeneca and GlaxoSmithKline, we are developing capabilities to print bespoke drugs. The injet technology will allow the dose and the matrix to release the drug when and where it is needed, from fast disintegrating tablets, fast melting tablets, to polypills. 


Centre for Additive Manufacturing 

Advanced Materials Research Group (Engineering)


We are also developing methods for the continuous manufacture of nanoparticles using microfluidics. 


Advanced Materials and Healthcare Technologies (Pharmacy) 


Samples of new drugs

Future Targeted Healthcare Manufacturing Hub

The University of Nottingham is part of the £20m EPSRC Future Targeted Healthcare Manufacturing Hub (led by UCL) 

In partnership with 30 industrial companies, the Future Targeted Healthcare Manufacturing Hub will address the manufacturing, business and regulatory challenges to ensure that new targeted biological medicines can be developed quickly and manufactured at a cost affordable to society.

The research spans stratified protein medicines targeted to particular patient groups through to truly personalised cell-based medicines.

Lead expert: Jon Aylott, Professor of Analytical Science

Advanced Materials and Healthcare Technologies Division




Chris Moody discussing drug discovery

Accelerating discovery of new medicines

A new £12 million partnership between the Universities of Nottingham and Strathclyde and pharmaceutical company GSK will accelerate research into the discovery of new medicines.

The five-year ESPRC funded programme will see the partners deliver a new suite of methods and approaches to tackle some of the major challenges in the discovery, development, and manufacture of medicines.  

The research programme aims to enable the production of transformative medicines at lower costs with reduced waste production and shorter time for manufacture. 

Focus areas include:

  • Use of Artificial Intelligence and machine learning to identify next generation medicines (Jonathan Hirst, Professor of Computational Chemistry)
  • Next generation catalysis and synthesis 
  • Sustainable processes for scale-up (Peter Licence, Professor of Chemistry)
  • Digital manufacture (Ricky Wildman, Professor of Multiphase Flow and Mechanics)

Details of the grant

Press release on the award



Drug manufacture using light

Design of reactors to manufacture medicines

We are using continuous photochemistry and electrochemistry with the aim of transforming the manufacture of pharmaceuticals and other chemicals, making it more sustainable.

The EPSRC-funded project, Photo-Electro: Transforming Chemical Synthesis, Discovery and Manufacture, is a partnership between the Universities of Nottingham, Bristol, and Southampton, alongside 25 industrial partners.


Photo-Electro project website

Applying green chemistry to the photochemical route to artemisinin